Test your knowledge of bispecific antibody management in relapsed multiple myeloma

Elranatamab is a bispecific antibody directed against CD3 and which of the following:
GPRC5D
SLAM7
BCMA
CD38
Elranatamab is a good option for someone relapsing after two lines of therapy.
True
False
What is the median onset of cytokine release syndrome?
7 days
4 days
2 days
14 days
0
{"name":"Test your knowledge of bispecific antibody management in relapsed multiple myeloma", "url":"https://www.poll-maker.com/Q764C2PCG","txt":"Elranatamab is a bispecific antibody directed against CD3 and which of the following:, Elranatamab is a good option for someone relapsing after two lines of therapy., What is the median onset of cytokine release syndrome?","img":"https://www.poll-maker.com/3012/images/ogquiz.png"}
Tools: Poll Maker | Quiz Maker